


[Download ebook] Specification of Drug Substances and Products: Development and Validation of Analytical Methods

# Specification of Drug Substances and Products: Development and Validation of Analytical Methods

*From Elsevier*

*audiobook / \*ebooks / Download PDF / ePub / DOC*



 Download

 Read Online

#1259137 in Books 2013-11-06 Original language: English PDF # 1 9.25 x 7.50 x .751, 2.15 #File Name: 0080983502390 pages | File size: 78.Mb

**From Elsevier : Specification of Drug Substances and Products: Development and Validation of Analytical Methods** before purchasing it in order to gauge whether or not it would be worth my time, and all praised Specification of Drug Substances and Products: Development and Validation of Analytical Methods:

0 of 0 people found the following review helpful. Five Stars By Melissa Marquez This book goes into a lot more detail regarding different methods. It's a must-have for any pharmaceutical scientist

Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of analytical methods.

This book is intended as more than a review of new regional guidelines, existing regulatory guidance, and industry practices. It provides a hands-on guide to understanding and applying these in practice. The authors discuss critical issues, novel approaches, and future directions while also providing insight into how International Guidelines were developed and the rationale behind them. Guide to industry best practices of analytical methodologies used in the specification of new drug substances and products (e.g. DOE, QbD) Critical assessment of the application of ICH guidelines on method validation and specification setting, written by experts involved in the development and application of the guidelines to aid understanding of requirements and what is expected by regulatory authorities Direct applicability to the day-to-day activities in drug development and the potential to increase productivity

"...a valuable addition to a pharmaceutical scientists library. relevant and of interest to various stake-holders in the drug development arena, including chemists, analysts, and programme managers. I can recommend it."--Organic Process Research Development Journal, Sep-14 "Its main role is to explain how to meet the most recent International Conference on Harmonization guidelines for drug development. The book is organized to offer a critical and comprehensive account of the approaches used to identify the key determinants of quality production that affect the safety, effectiveness, and marketability of a drug."--ProtoView.com, April 2014

From the Back Cover

Specification of Drug Substances and Products: Development and Validation of Analytical Methods is a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development and validation of analytical methods. This book is intended as more than a review of new regional guidelines, existing regulatory guidance, and industry practices. It provides a hands-on guide to understanding and applying these in practice. The authors discuss critical issues, novel approaches, and future directions while also providing insight into how International Guidelines were developed and the rationale behind them. Key features

- Guide to industry best practices of analytical methodologies used in the specification of new drug substances and products (e.g. DOE, QbD)
- Critical assessment of the application of ICH guidelines on method validation and specification setting, written by experts involved in the development and application of the guidelines to aid understanding of requirements and what is expected by regulatory authorities
- Includes extensive information on Residual Solvents, Inorganic impurities, Solid-state characterization, Chiral Methods, Extractables and Leachables, Pharmacopeial Methods and Tests, and more.

Christopher M. Riley is President of Riley and Rabel Consulting Services. He was Vice President of Analytical RD at DuPont Pharmaceutical Company, and Vice President of ChemPharm at ALZA (a division of Johnson and Johnson) as well as a member of the ICH Expert Working Group on Impurities. Thomas W. Rosanske is the Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee. Shelley R. Rabel Riley is an Assistant Professor of Chemistry in the Department of Natural Sciences at Northwest Missouri State University, as well as Vice-President of Riley and Rabel Consulting Services. She has previously held Principal Scientist positions at DuPont Pharmaceutical Company and ALZA (a division of Johnson and Johnson), and served as Director of Small Molecule Pharmaceutics at Amgen.

About the Author

President of Riley and Rabel Consulting Services. Former Vice President of Analytical RD at DuPont Pharmaceutical Company, and Vice President of ChemPharm at ALZA (a division of Johnson and Johnson) as well as a member of the ICH Expert Working Group on Impurities. Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee. Assistant Professor of Chemistry in the Department of Natural Sciences at Northwest Missouri State University, as well as Vice-President of Riley and Rabel Consulting Services. She has previously held Principal Scientist positions at DuPont Pharmaceutical Company and ALZA (a division of Johnson and Johnson), and served as Director of Small Molecule Pharmaceutics at Amgen.